Jasper Therapeutics, Inc.

Jasper Therapeutics is a clinical-stage biotechnology company focused on developing monoclonal antibodies and conditioning agents for mast cell-driven diseases and hematopoietic stem cell applications. The company's primary development focus centers on briquilimab, a monoclonal antibody candidate that blocks stem cell factor (SCF) signaling through the CD117 receptor on mast cells and hematopoietic stem cells. This mechanism targets the underlying pathology in multiple therapeutic indications.

The company's pipeline spans two primary disease areas. In mast cell-driven conditions, briquilimab is being developed for chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Additionally, Jasper is pursuing briquilimab as a conditioning agent for stem cell transplantation in patients with genetic blood disorders and immunodeficiencies, including sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. As a clinical-stage company, Jasper has not yet commercialized approved therapeutics and does not generate product revenues.

Based in Redwood City, California, the company operates with 27 full-time employees as of the most recent available data. Jasper was incorporated in Delaware and founded in 2018, with its shares listed on the Nasdaq exchange. The company's operations remain concentrated in its headquarters location.